This has sparked interest in finding alternative treatments. It’s why our research group at the School of Pharmacy at the University of the Western Cape, and others, are beginning to test the efficacy of curdlan as a potential drug candidate.
AuthorAdmire Dube
Admire Dube is an Associate Professor, Pharmaceutical Sciences, University of the Western Cape.
Admire Dube is a pharmaceutical scientist whose research focuses on developing nanoparticle drug delivery systems to improve treatment (i.e. nanomedicine) of infectious diseases, in particular tuberculosis which is endemic in South Africa. Following completion of a PhD in Pharmaceutical Sciences (focused on nanomedicine) at Monash University, Australia, in 2011, he took up a post-doctoral fellowship at the University at Buffalo, USA in the field of nanomedicine and infectious diseases. Thereafter he worked as a senior researcher at the Council for Scientific and Industrial Research in Pretoria, developing and commercializing nanomedicines for infectious diseases. He is currently employed as an Associate Professor in the discipline of Pharmaceutics within the School of Pharmacy, at the University of the Western Cape, Cape Town, South Africa. He is the principal investigator on an United States National Institutes of Health funded project developing immunotherapeutic nanoparticles for the treatment of tuberculosis. His long-term goal is to drive clinical translation of nanomedicines for infectious diseases in Africa.